@article{FeketeKulpokTaurinesetal.2023, author = {Fekete, Stefanie and Kulpok, Christine and Taurines, Regina and Egberts, Karin and Geissler, Julia and Gerlach, Manfred and Malonga Makosi, Doroth{\´e}e and K{\"o}nig, Jochem and Urschitz, Michael S. and Toni, Irmgard and Neubert, Antje and Romanos, Marcel}, title = {Value of a web-based pediatric drug information system to prevent serious adverse drug reactions in child and adolescent psychiatry}, series = {Journal of Neural Transmission}, volume = {130}, journal = {Journal of Neural Transmission}, number = {1}, doi = {10.1007/s00702-022-02563-9}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-324817}, pages = {53-63}, year = {2023}, abstract = {Psychotropic drugs are frequently prescribed 'off-label' to children and adolescents and carry the risk of serious adverse drug reactions (sADR). We examined the frequency of sADRs of psychotropic drugs in pediatric inpatients and explored their potential preventability through following the recommendations of a web-based pediatric drug information system (PDIS). The potential socio-economic impacts of using this online system is also addressed. Routine clinical data from all inpatients treated in a child and adolescent psychiatry department between January 2017 and December 2018 were retrospectively examined for the occurrence of sADRs as defined by the European Medicines Agency. The preventability of the sADRs was assessed based on the information of the PDIS. Furthermore, the expected prolongation of the hospital stay due to sADRs was calculated as well as the associated treatment costs. The study was supported by the Innovation Fund of the Joint Federal Committee, grant number 01NVF16021. In total, 1036 patients were screened of whom 658 (63.5\%) received psychopharmacological treatment. In 53 (8.1\%) of these patients 54 sADRs were documented, of which 37 sADRs were identified as potentially preventable through PDIS. Mitigating sADR through PDIS would likely have prevented prolonged hospital stays and conferred considerable savings for health insurance companies. PDIS provides systematic and evidence-based information about pediatric psychopharmacotherapy and helps to prevent prescribing errors. Therefore, PDIS is a useful tool to increase drug therapy safety in child and adolescent psychiatry. Further prospective studies are needed to confirm the results.}, language = {en} } @article{FrankeConzelmannGruenblattetal.2019, author = {Franke, Maximilian and Conzelmann, Annette and Gr{\"u}nblatt, Edna and Werling, Anna M. and Spieles, Helen and Wewetzer, Christoph and Warnke, Andreas and Romanos, Marcel and Walitza, Susanne and Renner, Tobias J.}, title = {No Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Adolescents}, series = {Frontiers in Molecular Neuroscience}, volume = {12}, journal = {Frontiers in Molecular Neuroscience}, doi = {10.3389/fnmol.2019.00112}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-229051}, year = {2019}, abstract = {Obsessive-compulsive disorder (OCD) causes severe distress and is therefore counted by the World Health Organisation (WHO) as one of the 10 most impairing illnesses. There is evidence for a strong genetic underpinning especially in early onset OCD (eoOCD). Though several genes involved in neurotransmission have been reported as candidates, there is still a need to identify new pathways. In this study, we focussed on genetic variants of the Neuropeptide Y (NPY) system. NPY is one of the most abundant neuropeptides in the human brain with emerging evidence of capacity to modulate stress response, which is of high relevance in OCD. We focussed on tag-SNPs of NPY and its receptor gene NPY1R in a family-based approach. The sample comprised 86 patients (children and adolescents) with eoOCD with both their biological parents. However, this first study on genetic variants of the NPY-system could not confirm the association between the investigated SNPs and eoOCD. Based on the small sample size results have to be interpreted as preliminary and should be replicated in larger samples. However, also in an additional GWAS analysis in a large sample, we could not observe an associations between NPY and OCD. Overall, these preliminary results point to a minor role of NPY on the stress response of OCD.}, language = {en} } @phdthesis{Frey2022, author = {Frey, Lillien Mara}, title = {Furchtgeneralisierung und Attentional Bias bei Kindern und Jugendlichen mit einer St{\"o}rung des Sozialverhaltens}, doi = {10.25972/OPUS-25974}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-259746}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2022}, abstract = {Bereits vorangegangene Studien haben zeigen k{\"o}nnen, dass eine verst{\"a}rke Generali- sierung von Furcht sowohl bei Erwachsenen, bei denen beispielsweise eine Angstst{\"o}rung oder eine PTSB diagnostiziert wurde, aber auch bei gesunden Kindern eine Rolle spielt. In unserer Studie untersuchten wir eine Gruppe Kinder und Jugendliche (n = 31, m = 25, w = 6; Alter = 13.35 ± 2.03), die eine St{\"o}rung des Sozialverhaltens aufwiesen, auf die Konditionierbarkeit von Furcht und eine m{\"o}gliche Furchtgeneralisierung. Diese Gruppe verglichen wir mit einer gesunden Kontrollgruppe (n = 29, m = 11, w = 18; Alter = 14.28 ± 2.43). Als Generalisierungsstimuli verwendeten wir ein Furchtgeneralisierungsparadigma mit zwei Frauengesichtern, die in vier Schritten aneinander angeglichen wurden. Zus{\"a}tzlich f{\"u}hrten wir mit beiden Probandengruppen ein Dot-Probe-Paradigma zur Objektivierung von Aufmerksamkeitsprozessen im Sinne eines Attentional Bias oder Attentional Avoidance mit emotionalen Gesichtern durch. Wir konnten eine erfolgreiche Furchtkonditionierung f{\"u}r beide Gruppen erreichen. Im Vergleich mit der gesunden Kontrollgruppe zeigte die externalisierende Probandengruppe eine verst{\"a}rke Furchtgeneralisierung. Hinsichtlich der subjektiven Valenz- und Kontingenzratings wurden die Unterschiede besonders deutlich. Eine verst{\"a}rkte Generalisierungsneigung bei erh{\"o}hter Trait-Angst konnten wir nicht finden. Die externalisierende Gruppe zeigte im Vergleich mit neutralen Gesichtern bei den emotionalen Gesichtern insgesamt einen Attentional Bias. Am deutlichsten war dabei eine verst{\"a}rkte Aufmerksamkeitslenkung hin zu gl{\"u}cklichen Gesichtern festzustellen. F{\"u}r die gesunde Kontrollgruppe konnten wir keine Besonderheiten bez{\"u}glich der Aufmerksamkeitsrichtung finden. Weiterf{\"u}hrende Studien sollten mit gr{\"o}ß- eren Probandengruppen und nach Geschlecht und Alter gepaarten Probanden durch- gef{\"u}hrt werden. Mit externalisierenden Probanden sollte ein Furchtgeneralisierungs- paradigma mit neutralen Stimuli (z.B. Ringe) gew{\"a}hlt werden, um eine subjektive Wertung emotionaler Gesichter bei den Ratings als St{\"o}rfaktor auszuschließen. F{\"u}r externalisierende Probanden sollte außerdem die Auspr{\"a}gung von CU-Traits erfasst und die Dauer der Testung verk{\"u}rzt oder auf zwei Termine aufgeteilt werden, um eine ausreichende Konzentrationsf{\"a}higkeit zu erm{\"o}glichen.}, subject = {Psychische St{\"o}rung}, language = {de} } @article{FoeckerTimmesfeldBuehlmeieretal.2021, author = {F{\"o}cker, Manuel and Timmesfeld, Nina and B{\"u}hlmeier, Judith and Zwanziger, Denise and F{\"u}hrer, Dagmar and Grasemann, Corinna and Ehrlich, Stefan and Egberts, Karin and Fleischhaker, Christian and Wewetzer, Christoph and Wessing, Ida and Seitz, Jochen and Herpertz-Dahlmann, Beate and Hebebrand, Johannes and Libuda, Lars}, title = {Vitamin D level trajectories of adolescent patients with anorexia nervosa at inpatient admission, during treatment, and at one year follow up: association with depressive symptoms}, series = {Nutrients}, volume = {13}, journal = {Nutrients}, number = {7}, issn = {2072-6643}, doi = {10.3390/nu13072356}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-242662}, year = {2021}, abstract = {(1) Background: Evidence has accumulated that patients with anorexia nervosa (AN) are at higher risk for vitamin D deficiency than healthy controls. In epidemiologic studies, low 25(OH) vitamin D (25(OH)D) levels were associated with depression. This study analyzed the relationship between 25(OH)D serum levels in adolescent patients and AN and depressive symptoms over the course of treatment. (2) Methods: 25(OH)D levels and depressive symptoms were analyzed in 93 adolescent (in-)patients with AN from the Anorexia Nervosa Day patient versus Inpatient (ANDI) multicenter trial at clinic admission, discharge, and 1 year follow up. Mixed regression models were used to analyze the relationship between 25(OH)D levels and depressive symptoms assessed by the Beck Depression Inventory (BDI-II). (3) Results: Although mean 25(OH)D levels constantly remained in recommended ranges (≥50 nmol/L) during AN treatment, levels decreased from (in)patient admission to 1 year follow up. Levels of 25(OH)D were neither cross-sectionally, prospectively, nor longitudinally associated with the BDI-II score. (4) Conclusions: This study did not confirm that 25(OH)D levels are associated with depressive symptoms in patients with AN. However, increasing risks of vitamin D deficiency over the course of AN treatment indicate that clinicians should monitor 25(OH)D levels.}, language = {en} } @article{GeisslerJansBanaschewskietal.2018, author = {Geissler, Julia and Jans, Thomas and Banaschewski, Tobias and Becker, Katja and Renner, Tobias and Brandeis, Daniel and D{\"o}pfner, Manfred and Dose, Christina and Hautmann, Christopher and Holtmann, Martin and Jenkner, Carolin and Millenet, Sabina and Romanos, Marcel}, title = {Individualised short-term therapy for adolescents impaired by attention-deficit/hyperactivity disorder despite previous routine care treatment (ESCAadol)-Study protocol of a randomised controlled trial within the consortium ESCAlife}, series = {Trials}, volume = {19}, journal = {Trials}, number = {254}, doi = {10.1186/s13063-018-2635-2}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176061}, year = {2018}, abstract = {Background: Despite the high persistence rate of attention-deficit/hyperactivity disorder (ADHD) throughout the lifespan, there is a considerable gap in knowledge regarding effective treatment strategies for adolescents with ADHD. This group in particular often shows substantial psychosocial impairment, low compliance and insufficient response to psychopharmacological interventions. Effective and feasible treatments should further consider the developmental shift in ADHD symptoms, comorbidity and psychosocial adversity as well as family dysfunction. Thus, individualised interventions for adolescent ADHD should comprise a multimodal treatment strategy. The randomised controlled ESCAadol study addresses the needs of this patient group and compares the outcome of short-term cognitive behavioural therapy with parent-based telephone-assisted self-help. Methods/design: In step 1, 160 adolescents aged 12 to 17 years with a diagnosis of ADHD will undergo a treatment as usual (TAU) observation phase of 1 month. In step 2, those still severely affected are randomised to the intervention group with an Individualised Modular Treatment Programme (IMTP) or a telephone-assisted self-help programme for parents (TASH) as an active control condition. The IMTP was specifically designed for the needs of adolescent ADHD. It comprises 10 sessions of individual cognitive behavioural therapy with the adolescents and/or the parents, for which participants choose three out of 10 available focus modules (e.g. organisational skills and planning, emotion regulation, problem solving and stress management, dysfunctional family communication). TASH combines a bibliotherapeutic component with 10 counselling sessions for the parents via telephone. Primary outcome is the change in ADHD symptoms in a clinician-rated diagnostic interview. Outcomes are assessed at inclusion into the study, after the TAU phase, after the intervention phase and after a further 12-week follow-up period. The primary statistical analysis will be by intention-to-treat, using linear regression models. Additionally, we will analyse psychometric and biological predictors and moderators of treatment response. Discussion: ESCAadol compares two short-term non-pharmacological interventions as cost-efficient and feasible treatment options for adolescent ADHD, addressing the specific needs and obstacles to treatment success in this group. We aim to contribute to personalised medicine for adolescent ADHD intended to be implemented in routine clinical care.}, language = {en} } @article{GeisslerWernerDworschaketal.2021, author = {Geissler, Julia M. and Werner, Elisabeth and Dworschak, Wolfgang and Romanos, Marcel and Ratz, Christoph}, title = {German Law Reform Does Not Reduce the Prevalence of Coercive Measures in Residential Institutions for Children, Adolescents, and Young Adults With Intellectual and Developmental Disabilities}, series = {Frontiers in Psychiatry}, volume = {12}, journal = {Frontiers in Psychiatry}, issn = {1664-0640}, doi = {10.3389/fpsyt.2021.765830}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-249030}, year = {2021}, abstract = {Background: Approximately 10\% of children, adolescents and young adults with an intellectual and developmental disability (IDD) in Bavaria live in residential institutions. 2015 saw media reports raising suspicions about excessive use of coercive measures (cM) in those institutions. Until a law reform at the end of 2017 made permission from family courts mandatory for cM, their use was governed by parental consent. The REDUGIA project conducted a representative survey comparing cM and their relation to challenging behaviour (cB) and employee stress in Bavaria pre and post reform. Methods: We sent questionnaires to 65 residential institutions for children, adolescents and young adults with IDD in 2017 (pre reform, T1) and 2019 (post reform, T2). To assess changes, we analysed data from all available questionnaire pairs (T1 and T2, N = 43). We calculated paired t-test and correlative analyses concerning the relationship between cB, cM, and employee stress. Results: The number of residents overall (T1: N = 1,661; T2: N = 1,673) and per institution (T1: m = 38.6 ± 32.0; T2: m = 38.9 ± 34.5, p = 0.920) remained stable. We did not see any changes in the Index cB (p = 0.508) or the proportion of residents per institution displaying various types of challenging behaviour (all ps>0.220). There was no change in the Index cM (p = 0.089) or any indicator of employee stress, all ps > 0.323. At follow-up, the Index cB correlated positively with the Index cM (r = 0.519 p < 0.001). Regarding employee stress, the Index cB correlated positively with the frequency of sick leave (r = 0.322, p = 0.037) and physical attacks on employees (r = 0.552, p < 0.001). The Index cM also correlated positively with the frequency of sick leave (r = 0.340, p = 0.028) and physical attacks on employees (r = 0.492, p = 0.001). Discussion: Coercive measures are not a general phenomenon, but are focused on specialised institutions. The law reform did not lead to changes in the number of children, adolescents and young adults with IDD affected by coercive measures in residential institutions in Bavaria. There were still large discrepancies between institutions in the prevalence of challenging behaviour and coercive measures. Coercive measures were associated with challenging behaviour and employee stress. Taken together, findings from REDUGIA emphasise the need to prevent challenging behaviour and thus coercive measures.}, language = {en} } @article{GeisslerWernerDworschaketal.2021, author = {Geissler, Julia and Werner, Elisabeth and Dworschak, Wolfgang and Romanos, Marcel and Ratz, Christoph}, title = {Freiheitsentziehende Maßnahmen in bayerischen Heimeinrichtungen f{\"u}r Kinder, Jugendliche und junge Vollj{\"a}hrige mit Intelligenzminderung}, series = {Zeitschrift f{\"u}r Kinder- und Jugendpsychiatrie und Psychotherapie}, volume = {49}, journal = {Zeitschrift f{\"u}r Kinder- und Jugendpsychiatrie und Psychotherapie}, number = {4}, issn = {1422-4917}, doi = {10.1024/1422-4917/a000808}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-244859}, pages = {273-283}, year = {2021}, abstract = {Fragestellung: In Bayern leben etwa 10 \% aller jungen Menschen mit Intelligenzminderung in Heimeinrichtungen. 2016 wurde in Presseberichten der Vorwurf unzul{\"a}ssiger freiheitsentziehender Maßnahmen formuliert. Im Rahmen des Projekts REDUGIA wurde in bayerischen Heimeinrichtungen eine repr{\"a}sentative Erhebung zu freiheitsentziehenden Maßnahmen (FeM), herausforderndem Verhalten (hfV) und der Mitarbeiterbelastung (MaB) durchgef{\"u}hrt. Methodik: 65 Einrichtungen f{\"u}r junge Menschen mit Intelligenzminderung in Bayern wurde ein Fragebogen zu strukturellen Gegebenheiten sowie MaB, hfV und FeM zugesendet. Neben deskriptiven Auswertungen wurden korrelative Analysen bzw. Regressionsanalysen zum Zusammenhang zwischen hfV, FeM und MaB durchgef{\"u}hrt. Ergebnisse: Es wurden Daten zu 1839 Personen in 61 Einrichtungen erhoben. 84.3 \% der Einrichtungen berichteten geringe Raten an hfV und FeM, w{\"a}hrend 15.7 \% ein geh{\"a}uftes Vorkommen von hfV und FeM angaben. Auf n = 1809 Vollzeit{\"a}quivalente kam es innerhalb von 14 Tagen zu 639 k{\"o}rperlichen Angriffen durch Bewohner_innen. In 12 Monaten wurden problemverhaltensassoziiert 85 Krankmeldungen sowie 33 Versetzungsantr{\"a}ge/K{\"u}ndigungen berichtet. Es zeigte sich ein signifikant positiver Zusammenhang zwischen hfV und FeM (R² = .307, F = 21.719, p < .001). Die Mitarbeiterbelastung korrelierte positiv mit hfV (r = .507, p < .001). Schlussfolgerungen: Die Studienbefunde weisen darauf hin, dass hfV sowie FeM bei jungen Menschen mit Intelligenzminderung kein fl{\"a}chendeckendes Ph{\"a}nomen darstellen, sondern sich auf wenige spezialisierte Einrichtungen fokussieren. M{\"o}gliche Maßnahmen zur Pr{\"a}vention von Problemverhalten und Freiheitsentzug werden diskutiert.}, language = {de} } @article{GerlachMaetzlerBroichetal.2012, author = {Gerlach, Manfred and Maetzler, Walter and Broich, Karl and Hampel, Harald and Rems, Lucas and Reum, Torsten and Riederer, Peter and St{\"a}ffler, Albrecht and Streffer, Johannes and Berg, Daniela}, title = {Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics}, series = {Journal of Neural Transmission}, volume = {119}, journal = {Journal of Neural Transmission}, number = {1}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125375}, pages = {39-52}, year = {2012}, abstract = {Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson's disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.}, language = {en} } @article{GerlachMaetzlerBroichetal.2011, author = {Gerlach, Manfred and Maetzler, Walter and Broich, Karl and Hampel, Harald and Rems, Lucas and Reum, Torsten and Riederer, Peter and St{\"o}ffler, Albrecht and Streffer, Johannes and Berg, Daniela}, title = {Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics}, series = {Journal of Neural Transmission}, volume = {119}, journal = {Journal of Neural Transmission}, number = {1}, doi = {10.1007/s00702-011-0682-x}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-133856}, pages = {39-52}, year = {2011}, abstract = {Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson's disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.}, language = {en} } @phdthesis{GernertgebBaranski2017, author = {Gernert [geb. Baranski], Stefanie}, title = {Assoziationsuntersuchung zu Neuropeptid Y-Polymorphismen bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivit{\"a}tsst{\"o}rung}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-155692}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2017}, abstract = {Die Aufmerksamkeitsdefizit-/Hyperaktivit{\"a}tsst{\"o}rung ist eine der h{\"a}ufigsten psychiatrischen Erkrankung des Kindesalters, die eine hohe Heritabilit{\"a}t aufweist und h{\"a}ufig bis ins Erwachsenenalter persistiert und lebenslang zu sozialen, gesundheitlichen und {\"o}konomischen Problemen f{\"u}hrt. Die ADHS tritt bei vielen Patienten in Kombina-tion mit anderen psychiatrischen und nicht-psychiatrischen Erkrankungen auf. In den letzten Jahren r{\"u}ckte zunehmend die h{\"a}ufig zur ADHS komorbid auftretende Adipositas in den Fokus der Forschung. Auf der Suche nach copy number variations in Zusammenhang mit ADHS, wurde eine Duplikation auf Chromosom 7p15 - dem Genlocus des NPY - entdeckt. NPY, ist ein endogenes orexigenes Peptid, welches physiologischerweise die Nahrungsaufnahme stimuliert und neben zahlreichen Effekten, wie Blutdruck- und Knochenregulation, auch in Zusammenhang mit neuropsychiatrischen Erkrankungen gebracht werden konnte. Diese Duplikation auf einem Genort, dessen Produkt f{\"u}r die Regulation von Energiehaushalt und K{\"o}rpergewicht zust{\"a}ndig ist, bildete die Grundlage, eine Assoziationsuntersuchung zu NPY-Genvarianten und dem K{\"o}rpergewicht bei Kindern durchzuf{\"u}hren. Untersucht wurden bei 269 an ADHS erkrankten Kindern und 142 gesunden Kontrollkindern die Assoziation zwischen NPY-Genvarianten (rs16147, rs16139, rs5574, rs16124) und ADHS, sowie die Assoziation zwischen NPY-Genvarianten und BMI-Perzentilen bei ADHS. Es ergab sich keine signifikante Assoziation bez{\"u}glich der aufgestellten Hypothesen.}, subject = {{\"U}bergewicht}, language = {de} }